Improving Publication Rates of Biomarker Results from Cancer Trials

摘要

Mandatory nondiagnostic biopsies for biomarker research pose risk and inconvenience to patients with cancer that should be justified by the knowledge gained. This commentary reflects on the publication by Freeman and Kimmelman, which points to a potentially low publication rate of biomarker results from cancer clinical trials requiring nondiagnostic biopsies. Clin Cancer Res; 18(23); 6398-9. (C) 2012 AACR.